English
简体中文
繁體中文
客服热线:400-1616-289
登录
注册
会议论文
Two-year follow-up data on the efficacy and safety of KN026, a HER2-targeted bispecific antibody combined with docetaxel as first-line treatment for HER2-positive recurrent/metastatic breast cancer
Zhang, Q.; Wang, J.; Ouyang, Q.; Wang, X.; Lin, D.; Wang, J.; Gan, L.; Ouyang, Z.; Xu, T.; Liu, Y.; Lv, Y.
哈尔滨医科大学; 厦门大学; 中山大学; 1
Annual Meeting of the European-Society-for-Medical-Oncology (ESMO)
2023-10
DOI: 10.1016/j.annonc.2023.09.595
6
阅读
引用
收藏
分享
相关
加载中…
文献加载失败,请重试
重试